In a 67‑year‑old man with alcoholic cirrhosis, hepatic encephalopathy, possible gastrointestinal bleed, and laboratory values showing pH 7.36, bicarbonate ≈16 mmol/L, pCO₂ ≈25 mm Hg, low anion gap and hyperchloremia, what is the most likely cause of his metabolic acidosis and what is the appropriate management?

ABG Interpretation and Metabolic Acidosis in Alcoholic Cirrhosis with GI Bleed

Primary Acid-Base Disorder

This patient has a non-anion gap (hyperchloremic) metabolic acidosis with appropriate respiratory compensation, most likely caused by lactulose-induced gastrointestinal bicarbonate losses, compounded by his underlying cirrhotic physiology.

The serial ABGs show:

• pH 7.36 (low-normal, trending toward acidemia)
• HCO₃⁻ 13–16 mmol/L (severely low)
• pCO₂ <20–25 mm Hg (compensatory hyperventilation)
• Anion gap 5–8 (low-normal, corrected for hypoalbuminemia remains low)
• Chloride 113–121 mmol/L (progressively elevated)

Mechanistic Analysis

Why Non-Anion Gap Acidosis?

The hyperchloremic (non-anion gap) pattern with chloride rising from 113 to 121 mmol/L indicates bicarbonate loss rather than unmeasured anion accumulation 1. In cirrhosis, the low anion gap (5–8) is primarily attributable to severe hypoalbuminemia (albumin 2.1–2.5 g/dL), which normally contributes ~2.5 mEq/L per g/dL to the anion gap 2. His corrected anion gap remains low-normal, ruling out significant lactate or unmeasured anion accumulation despite initial lactate elevation (3.9 → 1.7 mmol/L, now normalized).

Primary Cause: Lactulose-Induced GI Losses

The aggressive lactulose therapy (oral plus enemas targeting 3–4 bowel movements per 24 hours) is the dominant driver of this metabolic acidosis 3. Lactulose causes:

• Direct colonic bicarbonate secretion and loss
• Osmotic diarrhea with bicarbonate-rich stool losses
• Chloride retention by the kidney to maintain electroneutrality

The clinical note documents "possible GI losses yesterday with lactulose," and the progressive hyperchloremia (113 → 121 mmol/L) with falling bicarbonate (18 → 13 mmol/L) over 24–48 hours directly correlates with escalating lactulose therapy 4, 5.

Contributing Factors in Cirrhosis

While lactulose is the primary culprit, cirrhotic patients have baseline predisposition to acid-base disturbances 1, 4:

• Respiratory alkalosis (most common in cirrhosis) is present but overwhelmed by metabolic acidosis
• Hypoalbuminemic alkalosis (albumin 2.1–2.5 g/dL) provides ~6–8 mEq/L alkalinizing effect, partially offsetting the acidosis
• Renal tubular dysfunction in cirrhosis impairs distal acidification, though this typically causes type 4 RTA with hyperkalemia (not present here; K⁺ 3.2–3.7) 5

The absence of significant lactate (normalized to 1.7 mmol/L) and low ammonia trajectory (157 → improving) argue against tissue hypoperfusion or severe hepatic decompensation as primary drivers 1.

Clinical Implications and Management

Immediate Priorities

1. Titrate lactulose downward: The current regimen (oral + enemas) is excessive. Target 2–3 soft bowel movements daily, not 3–4 3. The 2023 French guidelines emphasize lactulose for hepatic encephalopathy but warn against over-diuresis and electrolyte disturbances as precipitants of HE 3.

2. Monitor electrolytes closely: The falling potassium (3.7 → 3.2 mmol/L) and bicarbonate (18 → 13 mmol/L) require 4–6 hour monitoring during lactulose adjustment. Hypokalemia worsens hepatic encephalopathy 3.

3. Consider polyethylene glycol (PEG) as alternative: The 2024 AASLD guidance on ACLF suggests PEG in patients at risk of ileus or electrolyte disturbances from lactulose 6. PEG causes less bicarbonate loss than lactulose.

4. Avoid bicarbonate replacement: With pH 7.36 and appropriate respiratory compensation (pCO₂ 25 mm Hg), bicarbonate therapy is not indicated and may precipitate paradoxical CNS acidosis or worsen hepatic encephalopathy 6.

Addressing Precipitating Factors for Hepatic Encephalopathy

The 2023 French guidelines identify gastrointestinal bleeding, infection, dehydration, and metabolic disorders as the key precipitants requiring control 3:

• GI bleed management: Continue ceftriaxone for SBP prophylaxis (correct per 2018 EASL guidelines for variceal bleeding) 7. The plan for EGD is appropriate.

• Avoid benzodiazepines: The guidelines strongly contraindicate benzodiazepines in decompensated cirrhosis (Grade 2+, Strong Agreement) 3. The clinical team correctly held benzodiazepines despite possible alcohol withdrawal.

• Rifaximin: Continue rifaximin 550 mg BID as add-on to lactulose for hepatic encephalopathy (Grade 2+, Strong Agreement) 3, 8. The 2014 AASLD/EASL guidelines establish rifaximin as the best-documented agent for preventing HE recurrence 8.

• PPI reassessment: The 2023 French guidelines recommend limiting PPIs to strict indications due to increased HE risk via dysbiosis and hyponatremia 3. However, in active GI bleeding, twice-daily PPI is justified short-term 7.

Monitoring Parameters

• Repeat BMP every 6–8 hours until bicarbonate stabilizes >16 mmol/L and chloride <115 mmol/L
• Daily ammonia levels are not recommended for routine monitoring 6, but trending improvement supports lactulose efficacy
• Sodium monitoring: Maintain Na⁺ >130 mmol/L (currently 139–141, adequate) per 2023 French guidelines, as hyponatremia <130 mmol/L predicts lactulose non-response 3

Pitfalls to Avoid

1. Over-correction with bicarbonate: The normalized pH (7.36) reflects appropriate respiratory compensation. Bicarbonate infusion risks rebound alkalosis, hypokalemia, and paradoxical CNS acidosis 6.

2. Continuing aggressive lactulose: The metabolic acidosis will worsen if lactulose is not reduced. The 2022 EASL guidelines note lactulose-induced diarrhea as a precipitant of metabolic disturbances 9.

3. Ignoring hypokalemia: Potassium 3.2 mmol/L requires repletion to >3.5 mmol/L. Hypokalemia worsens hepatic encephalopathy and predisposes to arrhythmias in the setting of cirrhosis 3, 4.

4. Misattributing acidosis to lactate: The initial lactate 3.9 mmol/L has normalized (1.7 mmol/L), and the anion gap remains low. This is not lactic acidosis from hypoperfusion 1.

Prognosis

The 2018 study on ACLF and acid-base status found that acidemia (pH <7.35) and metabolic acidosis independently predict 28-day mortality in cirrhosis, with pH <7.1 conferring 100% mortality 1. This patient's pH 7.36 places him at the threshold; preventing further acidemia is critical. The low MELD score (~20) and absence of ACLF criteria (no organ failures beyond hepatic encephalopathy) suggest reasonable short-term prognosis if precipitants are controlled 1.